Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
EvolveImmune United, Inc
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07217171CT.gov A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Squamous Cell Carcinoma Of Penis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Evolve104 (this asset) | EvolveImmune United, Inc | P1 | CC · 43 |
| Isocyclophosphamide | Institute of Cancer Research, United Kingdom | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Institute of Cancer Research, United Kingdom | P3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
| Rigosertib | Traws Pharma, Inc. | P2 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Pen-866 | Tarveda Therapeutics | P1/2 | CCC |
| Fluorouracilum | Tarveda Therapeutics | P1/2 | CCC |
+6 more in the Squamous Cell Carcinoma Of Penis cohort
Other indications for Evolve104
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Urethra Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Squamous Cell Lung Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Evolve104 in Squamous Cell Carcinoma Of Penis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/evolve104-squamous-cell-carcinoma-of-penis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →